TickerGuard
Buy Day today: Poor (52) Mixed market breadth · today: Core PCE (August) ≈
NBIX

Neurocrine Biosciences Inc

Healthcare · Drug Manufacturers - Specialty & Generic

138.90$ -0.4% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Balance Sheet

Neurocrine Biosciences Inc (NBIX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 5,359 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet NBIX
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
2,848 3,251 3,472 3,305 3,535 3,719 3,688 3,890 4,266 4,632 4,906 5,359
1,650 1,607 1,799 1,670 1,877 1,725 1,638 1,749 2,158 2,523 2,436 1,638
294 251 396 140 349 233 194 264 340 713 267 332
1,095 1,032 1,211 1,039 1,228 1,076 944 976 1,115 1,480 1,316 390
418 439 451 468 481 479 516 596 728 687 768 887
29 38 37 43 46 57 59 57 69 69 65 104
– 5.8 – 5.7 6.1 3.7 – – – – – 501
35 36 34 34 35 37 36 37 36 – – 2,226
846 1,019 1,086 796 816 1,129 1,152 1,196 1,262 1,378 1,499 1,666
692 655 713 399 430 508 523 546 638 743 832 875
188 170 259 35 35 – – – 51 – – –
94 133 87 107 96 100 110 105 120 105 120 142
2,002 2,232 2,386 2,509 2,719 2,590 2,536 2,694 3,004 3,253 3,407 3,694
-305 -157 -114 -49 81 29 -5.3 85 294 448 590 724
101 102 104 104 104 103 103 101 103 103 103 104

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?